Peptide that Enhances Bone Matrix Production

Novel small peptide that has the ability to augment bone matrix production, potentiating its use for the treatment of osteoporosis and other bone related diseases.

Millions of people suffer from osteoporosis, leading to painful fractures and placing billions of dollars of financial stress on the healthcare system. It has been shown that early diagnosis and treatment can reduce the fracture rate in osteoporosis patients. Most drugs available for the treatment of osteoporosis are anti-resorptives, which slow the course of bone resorption during bone remodeling but do not promote new bone growth. Alternatively, anabolic drugs stimulate osteoplast activity. Teriparatide is the only approved anabolic drug available. This drug must be injected daily and should not be used for more than three years. The limited clinical use of this drug leaves a large market for safe skeletal anabolic therapies.

Dr. Srinivas Pemtyala of the Department of Anesthesiology at Stony Brook University has discovered a short peptide, called CRP, that has the ability to augment bone matrix production. CRP increases bone matrix productions in pre- osteoblast cells and human fetal osteoblast cells in vitro. Further, CRP mobilizes calcium and increases the expression of osteocalcin, a maker for bone matrix production. Currently, the peptides are being evaluated in an OVX rat model to assess their effect on bone loss and bone fracture repair in vivo. It is believed that this peptide or its analogues can be used to treat bone related diseases, like osteoporosis, and bolster fracture healing.

CRP potentially utilizes a new mechanism of action. CRP may have utility in treating both osteoporosis and osteoporosis related fractures.

Treatment of osteoporosis and other degenerative bone diseases. Enhance the healing of osteoporosis related bone fractures.

PCT Publication No. WO 2012-078734

Proof of concept; some animal data available.

We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Available for License

Osteoporosis, Fractures, Bone matrix, Peptide

https://stonybrook.technologypublisher.com/files/sites/therapeutics1.jpg 

Patent Information:
Technology/Start-up ID: